OnKure Therapeutics (NASDAQ:OKUR) Issues Quarterly Earnings Results

Key Points

• OnKure reported a loss of ($1.11) per share for the quarter, missing the consensus estimate of ($0.74) by ($0.37).
• Shares traded down to $4.52; the company has a market cap of about $61.8 million and a 52‑week range of $1.70–$5.38, highlighting small‑cap volatility.
• Analyst coverage is limited and mixed (one Buy, one Hold, one Sell) but the average price target is $27.00, and institutional investors/hedge funds own about 90.98% of the stock.

OnKure Therapeutics (NASDAQ:OKUR - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.37), FiscalAI reports.

OnKure Therapeutics Price Performance

Shares of OKUR stock traded down $0.08 during trading hours on Tuesday, reaching $4.52. 95,002 shares of the company were exchanged, compared to its average volume of 234,204. OnKure Therapeutics has a fifty-two week low of $1.70 and a fifty-two week high of $5.38. The stock's fifty day moving average is $4.04 and its two-hundred day moving average is $3.30. The company has a market cap of $61.81 million, a price-to-earnings ratio of -1.02 and a beta of 0.36.

Wall Street Analysts Forecast Growth

OKUR has been the topic of several research analyst reports. Weiss Ratings raised shares of OnKure Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday, April 24th. HC Wainwright decreased their target price on OnKure Therapeutics from $34.00 to $27.00 and set a "buy" rating on the stock in a report on Monday, March 16th. Finally, Wall Street Zen upgraded OnKure Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, March 14th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, OnKure Therapeutics presently has an average rating of "Hold" and an average price target of $27.00.

Hedge Funds Weigh In On OnKure Therapeutics

A number of large investors have recently modified their holdings of the stock. ADAR1 Capital Management LLC acquired a new position in shares of OnKure Therapeutics during the fourth quarter worth approximately $2,941,000. Shay Capital LLC lifted its position in shares of OnKure Therapeutics by 17.4% during the third quarter. Shay Capital LLC now owns 917,934 shares of the company's stock worth $2,524,000 after purchasing an additional 135,888 shares in the last quarter. Prosight Management LP lifted its position in shares of OnKure Therapeutics by 204.9% during the fourth quarter. Prosight Management LP now owns 816,909 shares of the company's stock worth $2,369,000 after purchasing an additional 548,950 shares in the last quarter. Rosalind Advisors Inc. acquired a new position in shares of OnKure Therapeutics during the fourth quarter worth approximately $2,118,000. Finally, Renaissance Technologies LLC lifted its holdings in OnKure Therapeutics by 40.7% in the fourth quarter. Renaissance Technologies LLC now owns 247,350 shares of the company's stock valued at $717,000 after buying an additional 71,600 shares during the period. 90.98% of the stock is currently owned by institutional investors and hedge funds.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc NASDAQ: OKUR is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company's lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.